에 대한 최신 뉴스 Eyenovia (NASDAQ:EYEN) 주식

Eyenovia

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

News

EYEN

FUBO

PAYX

PYCR

TSX:CSO

TSX:TD

TSXV:CSO

VSTO

블록에 신규 등장 TD 은행, 또는 토론토 도미니언 은행(TSX:TD)이 찰스 슈왑에 대한 10.1% 지분 매각을 고려 중이다. 이 매각은 이 캐나다 은행의 미국 자금 세탁 스캔들에 따른 전략적 검토의 일환이다. TD 은행의 신임 CEO인 레이먼드 천(Raymond Chun)이 블룸버그에 이 과정을 확인했다.

딜 디스패치: TD 은행이 찰스 슈왑 지분을 판매할까? 아이노비아, 스마트 쉐어가 시장에

Eyenovia Inc

Tuesday, Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) reported fourth-quarter 2024 adjusted EPS of $1.90, <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $1.70</a>.
Sales increased 6% year over year to $7.57 billion, beating the consensus of $7.14 billion. This was primarily due to higher sales in the HIV segment, as well as in Oncology and Liver Disease. Sales were partially offset by lower <a href="https://www.benzinga.com/pressreleases/25/02/b43639858/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">sales of Veklury (remdesivir)</a>.
HIV sales increased 16% to $5.45 billion, <a target="_blank" href="https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/GILD-Q424-Summary-of-Prepared-Remarks-11-February-2025.pdf" rel="noreferrer noopener">driven</a> by demand, higher realized price, and favorable inventory dynamics.
Biktarvy sales for the quarter increased from $3.12 billion to $3.8 billion.
Liver disease sales increased 4% to $719 million, driven by a strong Livdelzi launch and increased HBV/HDV demand, partially offset by lower HCV sales from fewer patient starts.
Dividend: Gilead Sciences increased its quarterly cash dividend by 2.6% <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640030/gilead-sciences-announces-2-6-percent-increase-in-first-quarter-2025-dividend" rel="noreferrer noopener">to $0.79 per share</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing</a>
Guidance: Gilead expects 2025 adjusted EPS of $7.70-$8.10 versus the consensus of $7.58 and sales of $28.2 billion—$28.6 billion versus the consensus of $28.42 billion.
&#8220;From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV prevention,&#8221; said Daniel O'Day, Gilead's Chairman and CEO.
Piper Sandler raised Gilead&#8217;s price forecast from $105 to $110, with an <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">unchanged Overweight rating</a>. The analysts cited the upcoming commercial launch of lenacapavir in PrEP later this year and several notable late-stage readouts on tap.
After filing for regulatory approval of lenacapavir for PrEP last year, Gilead still expects a potential commercial launch in 2025. This could help the company secure its place in the PrEP market and improve patient adherence. It will also strengthen its HIV leadership into the late 2030s.
Goldman Sachs writes that Gilead is well-positioned for the lenacapavir launch.
On the HIV business, Goldman Sachs analyst Salveen Richter says commentary was largely consistent with the recent investor event.
The analyst sees challenges in oncology due to competition affecting Kite and Trodelvy but remains positive on Arcellx Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) partnered therapy, anito-cel, for multiple myeloma and is keeping an eye on Trodelvy&#8217;s expansion.
Needham analyst Joseph Stringer sees two key events driving value in 2025: the anticipated launch of lenacapavir for HIV prevention and Phase 3 trial updates for Trodelvy in first-line metastatic triple-negative breast cancer.
The analyst maintains a Hold rating on Gilead, citing a balanced risk/reward at current levels. However, Needham is growing more optimistic about the stock. The analysts credit the strong performance of Gilead's HIV business, improving profit margins, and lenacapavir's potential to boost revenue.
Price Action: Gilead Sciences stock is up 7.73% at $103.57 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43665455/te-connectivity-snaps-up-richards-manufacturing-for-2-3-billion-details" target="_blank" rel="noreferrer noopener">TE Connectivity Snaps Up Richards Manufacturing For $2.3 Billion: Details</a></li>
</ul>
Image via Gilead Sciences

Analyst Color

Biotech

Earnings

Large Cap

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ACLX

GILD

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Technology giant, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), which reported earnings last week, remains <a href="https://www.benzinga.com/topic/amazon">one of the top holdings </a>in Dan Loeb's Third Point LLC portfolio.
However, Loeb has had a complex relationship with the stock, adjusting his stake multiple times over the past <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml">two </a>years.
Stake History: The stock entered the investor&#8217;s top list when he held <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514623003432/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">4.1 </a>million shares in the second quarter of FY23
The investor then raised the stake to <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514623004511/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">4.7 </a>million in the third quarter of FY23, followed by trimming the shares to <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624001503/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">4.2 </a>million in the fourth quarter of FY23 and thereafter increasing the stock holding to <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624002645/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">5.1 </a>million in the first quarter <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624004004/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">of </a>FY24.
Further, Loeb maintained the stake in the second quarter of FY24 but trimmed the stake to 3.7 million <a href="https://www.benzinga.com/news/large-cap/25/02/43444040/dan-loebs-third-point-trims-amazon-microsoft-meta-as-tech-stocks-climb" target="_blank" rel="noreferrer noopener">in the third quarter of FY24</a>.
Read More: <a href="https://www.benzinga.com//node/43550696" target="_blank" rel="noreferrer noopener">Amazon To Pour Nearly&nbsp;$100 Billion&nbsp;Into AI In 2025, Surpassing Microsoft And Alphabet—Andy Jassy Says &#8216;Cost Of Inference Will Meaningfully Come Down&#8217; Amid DeepSeek Worries</a>
Earnings Results: On Feb. 6, the company reported fourth-quarter net sales of $187.8 billion, up 10% year-over-year (Y/Y), which beat a Street consensus estimate of $187.3 billion and EPS of $1.86, beating a <a href="https://www.benzinga.com/25/02/43545590/amazoncom-q4-earnings-highlights-revenue-beat-eps-beat-most-successful-holiday-shopping-season-in-company-history" target="_blank" rel="noreferrer noopener">consensus estimate of $1.48</a>.
Amazon guided for first-quarter net sales to come in a range of $151 billion to $155.5 billion, up 5% to 9% Y/Y, which fell short <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">of the consensus of $158.5 billion</a>.
Amazon indicated a potential unfavorable impact of $2.1 billion due to foreign exchange rates in the first quarter. Additionally, it stated that the Leap Year could affect net sales by approximately $1.5 billion.
Several analysts boosted the price forecast for the company following strong fourth-quarter results, with RBC Capital analyst Brad Erickson maintaining an Outperform rating and raising the price <a target="_blank" href="https://www.benzinga.com/quote/AMZN/analyst-ratings" rel="noreferrer noopener">forecast from $255 to $265</a>.
Erickson said, &#8220;While the name is crowded and the AI ‘spend money to make money&#8217; debate will undoubtedly continue, the combo of AWS&#8217;s high margin growth and further network cost efficiencies have the company poised to continue growing earnings at<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43569359/amazon-analysts-flag-q1-guidance-concerns-ai-investment-surge" rel="noreferrer noopener"> a level supportive of this valuation,&#8221;</a>.&nbsp;
Meanwhile, DA Davidson analyst Gil Luria reiterated a Buy rating and upped the price forecast from $235 to $280, saying that &#8220;AWS winning in AI with better investment discipline,&#8221;.
Amazon's share has increased 38.02% in the last year, outperforming the&nbsp;Fidelity MSCI Consumer Discretionary Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDIS#NYSE">FDIS</a>), which has&nbsp;surged 24.52%, but underperformed ProShares Online Retail ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>) that witnessed a growth of 43.92% over the same time frame.
Compared to its top peers, Amazon shares underperformed Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), which grew 57.51%, but outperformed PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), which declined 8.96% and MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), which rose 19.28% in the last one year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43649078/shopify-secures-12-of-us-e-commerce-pie-as-reebok-champion-and-warner-music-join-platform" target="_blank" rel="noreferrer noopener">Shopify Secures 12% Of US E-Commerce Pie As Reebok, Champion, And Warner Music Join Platform</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

AMZN

BABA

FDIS

MELI

ONLN

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Dan Loeb's Amazon Stake Moves: A Look At His Trading Shifts

WIIM

RDFN

Redfin shares are trading higher after the company announced a partnership making Zillow the exclusive provider of multifamily rental listings.

Barrick Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) shares are trading higher Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com/25/02/43657514/barrick-gold-q4-higher-realized-gold-prices-lower-aisc-but-revenue-falls-short">fourth-quarter earnings</a> and announced a new $1 billion stock buyback program.
What To Know: The company's fourth-quarter revenue came in at $3.645 billion, up 8% from the previous quarter but missing analyst estimates of $3.978 billion. Barrick reported adjusted earnings per share of 46 cents, beating Wall Street's expectation of 41 cents. 
CEO Mark Bristow highlighted steady operational improvements across several key projects, including Pueblo Viejo, Veladero and Nevada Gold Mines. He noted that the company had made progress at Kibali while advancing major feasibility studies for the Lumwana and Reko Diq projects. Despite concerns surrounding Barrick's exposure to Mali, Bristow emphasized that the company's fundamental value remains strong.
Barrick also authorized a new $1 billion buyback program, replacing its previous program, which had repurchased $498 million in shares.
For 2025, Barrick expects gold production between 3.15 million and 3.5 million ounces, with all-in-sustaining costs projected between $1,460 and $1,560 per ounce. Capital expenditures are forecasted to be between $3.1 billion and $3.6 billion and copper production is expected to range between 200,000 and 230,000 tonnes, driven by higher output at Lumwana.
GOLD Price Action: Barrick Gold shares were up 6.47% at $18.18 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021225&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-1024x540.png" alt="" class="wp-image-779507" style="width:500px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12143534/Screenshot-2025-02-12-at-14.35.10.png 1505w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/opinion/25/02/43671549/the-perfect-stocks-portfolio-global-value-investing-in-a-changing-worldhttps://www.benzinga.com/opinion/25/02/43671549/the-perfect-stocks-portfolio-global-value-investing-in-a-changing-world">The Perfect Stocks Portfolio: Global Value Investing in a Changing World</a></li>
</ul>
Image Via Shutterstock.

GOLD

Barrick Gold Shares Gain After Q4 Earnings And New $1 Billion Buyback Program

Deep-pocketed investors have adopted a bullish approach towards Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GOLD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 30 extraordinary options activities for Barrick Gold. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 43% bearish. Among these notable options, 8 are puts, totaling $398,820, and 22 are calls, amounting to $1,569,465.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $13.0 and $22.0 for Barrick Gold, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Barrick Gold options trades today is 9536.76 with a total volume of 22,863.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Barrick Gold's big money trades within a strike price range of $13.0 to $22.0 over the last 30 days.
<h3>Barrick Gold Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739391332_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.43</td>
<td>$2.38</td>
<td>$2.42</td>
<td>$16.00</td>
<td>$241.2K</td>
<td>2.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.25</td>
<td>$15.00</td>
<td>$210.8K</td>
<td>56.7K</td>
<td>917</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$15.00</td>
<td>$118.5K</td>
<td>1.5K</td>
<td>517</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$2.26</td>
<td>$2.13</td>
<td>$2.2</td>
<td>$16.00</td>
<td>$110.0K</td>
<td>4.9K</td>
<td>686</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.8</td>
<td>$18.00</td>
<td>$85.1K</td>
<td>881</td>
<td>338</td>
</tr>
</tbody>
</table>

<h3>About Barrick Gold</h3>
Based in Toronto, Barrick Gold is one of the world's largest gold miners. In 2023, the firm produced nearly 4.1 million attributable ounces of gold and about 420 million pounds of copper. At year-end 2023, Barrick had about two decades of gold reserves along with significant copper reserves. After buying Randgold in 2019 and combining its Nevada mines in a joint venture with competitor Newmont later that year, it operates mines in 19 countries in the Americas, Africa, the Middle East, and Asia. The company also has growing copper exposure. Its potential Reko Diq project in Pakistan, if developed, could double copper production by the end of the decade.
Following our analysis of the options activities associated with Barrick Gold, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Barrick Gold</h3>
<ul>
<li>Trading volume stands at 31,893,320, with GOLD's price up by 6.41%, positioned at $18.16.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Expert Opinions on Barrick Gold</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $18.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Perform, adjusting the price target to $19. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $18. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Barrick Gold, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Barrick Gold Unusual Options Activity

Financial giants have made a conspicuous bearish move on Baidu. Our analysis of options history for Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) revealed 85 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $379,837, and 79 were calls, valued at $5,968,898.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $170.0 for Baidu, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Baidu stands at 1958.74, with a total volume reaching 33,919.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Baidu, situated within the strike price corridor from $60.0 to $170.0, throughout the last 30 days.
<h3>Baidu 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739391327_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$10.25</td>
<td>$9.9</td>
<td>$10.0</td>
<td>$100.00</td>
<td>$998.0K</td>
<td>2.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.65</td>
<td>$18.55</td>
<td>$18.55</td>
<td>$80.00</td>
<td>$371.0K</td>
<td>1.6K</td>
<td>205</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$27.9</td>
<td>$26.25</td>
<td>$26.6</td>
<td>$90.00</td>
<td>$266.0K</td>
<td>645</td>
<td>129</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$22.8</td>
<td>$22.2</td>
<td>$22.5</td>
<td>$85.00</td>
<td>$112.4K</td>
<td>510</td>
<td>57</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.0</td>
<td>$9.45</td>
<td>$9.93</td>
<td>$90.00</td>
<td>$99.3K</td>
<td>1.2K</td>
<td>431</td>
</tr>
</tbody>
</table>

<h3>About Baidu</h3>
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
<h3>Present Market Standing of Baidu</h3>
<ul>
<li>With a trading volume of 5,480,640, the price of BIDU is up by 4.6%, reaching $93.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Baidu</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $112.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Baidu, which currently sits at a price target of $95. 
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $130.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Baidu, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

BIDU

Baidu Unusual Options Activity For February 12

Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to $161,431.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $305.0 for Amgen over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 448.17 with a total volume of 924.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $280.0 to $305.0 over the last 30 days.
<h3>Amgen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739391322_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.25</td>
<td>$3.45</td>
<td>$305.00</td>
<td>$107.2K</td>
<td align="right">318</td>
<td align="right">408</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.35</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$47.7K</td>
<td align="right">344</td>
<td align="right">53</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.0</td>
<td>$8.95</td>
<td>$9.0</td>
<td>$300.00</td>
<td>$42.3K</td>
<td align="right">344</td>
<td align="right">100</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.5</td>
<td>$13.35</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$33.7K</td>
<td align="right">675</td>
<td align="right">54</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.65</td>
<td>$13.45</td>
<td>$13.5</td>
<td>$290.00</td>
<td>$31.0K</td>
<td align="right">675</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>With a volume of 1,356,099, the price of AMGN is down -0.63% at $294.81. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $305.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Amgen, targeting a price of $275. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Amgen with a target price of $295. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $324. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $329. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

AMGN

Amgen Unusual Options Activity For February 12

VALE

Brazil Presidential Palace Says Vale To Announce 70 Billion Reais Investment For 2025-2030 In Copper, Iron Ore In Brazil's Carajas; Vale's Investment Announcement To Be Made At Event On Friday With Brazil's President Lula

GRAL

GRAIL shares are trading lower after the company announced the initial phase of a program to improve provider access to GRAIL's Galleri multi-cancer early detection test.

CSX Corp 13G Filing Shows JPMorgan Chase & Co. Reported A 5.5% Stake In The Co As Of December 31, 2024

After a stellar 2024 and an outstanding first month of 2025, the world has again caught the gold bug. Geopolitical tensions, escalating tariff threats and fears of reappearing inflation have prompted <a href="https://www.benzinga.com/news/global/25/02/43514005/escalating-tariff-wars-tighter-african-supply-drive-gold-toward-3000-milestone">demand for physical metal</a>, causing disruptions, delays and sale suspensions.
South Korea is the latest country to face such a challenge. According <a href="https://www.bloomberg.com/news/articles/2025-02-12/south-korea-s-mint-halts-gold-bar-sales-as-supply-tightens">to</a> Bloomberg, the Korea Minting and Security Printing Corp, a state-owned coin issuer, has suspended sales.
Earlier this month, London's Gold Forward Offered Rate (GOFO) surged to 10% annually, far above the typical 2-3%. A supply shortage caused the Bank of England to announce <a href="https://in.benzinga.com/news/econ-s/25/01/43348204/gold-hits-record-high-as-central-banks-ease-stance-5-mining-stocks-rally">multi-week delivery delays</a>, prompting its gold to trade at a discount of over $5 per ounce compared to London&#8217;s spot price.
However, as institutions rush to move gold overseas, the logistical challenge of converting London&#8217;s 400-ounce bars into smaller, Comex-approved counterparts has added to delays. Leasing rates have also spiked to 4.7%, with central banks capitalizing on the demand by lending gold at higher premiums.
In 2024, these financial institutions added 1,045 tons of gold to their reserves <a href="https://www.gold.org/goldhub/research/gold-demand-trends/gold-demand-trends-full-year-2024/central-banks">per</a> World Gold Council. Barrick Gold's CEO Mark Bristow noted that "gold is becoming reserve currency for central banks" during the leading gold miner's Q4 earnings webcast.
Beyond short-term supply constraints, fears of a second wave of inflation add to gold's appeal. Today's 3% CPI came in hotter than expected, marking the fourth consecutive increase in annual inflation.
While another wave of global inflation is not inevitable, analysts at ING Research believe that inflation will be <a href="https://www.ing.com/Newsroom/News/Inflations-second-wave-Are-we-really-watching-a-70s-rerun.htm">structurally higher</a> and more volatile within the next years. However, they acknowledge that the past is not a perfect gauge for the future, given the vastly different environment preceding the inflation period, with two recessions and oil shocks.
Still, the domestic economy structure also looked vastly different back then. Through the 1970s, the government ran an average yearly <a href="https://clintonwhitehouse4.archives.gov/WH/New/html/surplus2.html">budget deficit of 2.7%</a>. In 2024, the deficit was 6.4%, while the Congressional Budget Office saw it at 6.5% in 2025. To plug this hole, the government needs to sell bonds and if the Federal Reserve is the buyer, directly or through programs like Quantitative Easing, the money supply grows, usually taking inflation along.
Read Next: <a href="https://www.benzinga.com/25/02/43651098/geopolitics-and-resource-nationalism-are-choking-the-commodity-supply">Geopolitics And Resource Nationalism Are Choking The Commodity Supply</a>
Photo: Shutterstock

Macro Economic Events

Commodities

Global

Economics

Inflation's Second-Wave Fears And Budget Deficits Support Gold's Record Pace

Crypto markets are stabilizing and trending <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43667278/bitcoin-sees-short-term-volatility-after-inflation-data-altseason-remains-distant">upward after an initial drop</a> following the higher-than-expected COnsumer Price Inflation report.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$97,166.74</td>
<td>+2.2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,679.72</td>
<td>+3.4%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$193.42</td>
<td>-1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.44</td>
<td>+2.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2612</td>
<td>+4.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001680</td>
<td>+8.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increased by 3.2% and daily active addresses grew by 2.6%. Transactions greater than $100,000 are up from 9,866 to 10,487 in a single day. Exchanges netflows are down by 192.3%.</li>
<li>Coinglass data reports 142,147 traders were liquidated in the past 24 hours for $310.39 million.</li>
<li>IntoTheBlock <a href="https://x.com/intotheblock/status/1889602444167918050">data</a> points out that the 1.6 million addresses that historically acquired 1.57 million BTC at an average price of 97,200 are now forming a resistance level. It also added that "these holders may sell near their breakeven amid market uncertainty, adding selling pressure and complicating any clear upward breakout."</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43667642/coinbase-expected-to-post-strong-earnings-as-trading-volume-hits-multi-year-high">Coinbase Expected To Post Strong Earnings As Trading Volume Hits Multi-Year High</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43646818/goldman-sachs-increases-bitcoin-etf-stake-over-1-5-billion-in-q4-reports-a-massive-1793-jump-in-ethereum-etf-holdings">Goldman Sachs Increases Bitcoin ETF Stake Over $1.5 Billion In Q4, Reports A Massive 1793% Jump In Ethereum ETF Holdings</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43658023/trump-to-nominate-ex-cftc-commissioner-brian-quintenz-as-agency-head">Trump To Nominate Ex-CFTC Commissioner Brian Quintenz As Agency Head</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43654402/el-salvador-proved-bitcoin-is-not-destined-to-be-money-analyst-says">El Salvador Proved &#8216;Bitcoin Is Not Destined To Be Money,&#8217; Analyst Says</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>PancakeSwap (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/cake/usd">CAKE</a>)</td>
<td>&nbsp;$2.63</td>
<td>+37.2%</td>
</tr>
<tr>
<td>Sonic (CRYPTO: S)</td>
<td>&nbsp;$0.5459</td>
<td>+23.7%</td>
</tr>
<tr>
<td>Onyxcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">XCN</a>)</td>
<td>&nbsp;$0.02332</td>
<td>+11.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices resuming uptrend, crypto trader DonAlt predicts its Bitcoin's time to break out.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Time to break out <a href="https://t.co/NPSTi8pbh7">pic.twitter.com/NPSTi8pbh7</a>
&mdash; DonAlt (@CryptoDonAlt) <a href="https://twitter.com/CryptoDonAlt/status/1889717070536835492?ref_src=twsrc%5Etfw">February 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto Chase <a href="https://x.com/Crypto_Chase/status/1889740312215515464">explained</a> that he is still holding Bitcoin long position from $95,600 after having survived 8 days of chop and the CPI release. 
He sees prices at local resistance, but traders are looking to take profits higher. 
The trader moved his stop loss to around $94,000 as local liquidity was swept and demand held, making a return to the lows unlikely.
Crypto trader Jelle sees Bitcoin is retesting mini range and a bounce will take it back to 100,000 while Scient <a href="https://x.com/Crypto_Scient/status/1889759391647150284">highlighted</a> on Bitcoin is showing strength on a bearish news, which is a net positive outlook in the near term.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Retesting mini range. Bounce here and we charge back to $100,000 next.<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/wMpCh0PKKe">pic.twitter.com/wMpCh0PKKe</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1889757090941403604?ref_src=twsrc%5Etfw">February 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43662831/bitcoin-meme-coins-dominate-crypto-but-other-projects-suffer-analyst-says">Bitcoin, Meme Coins Dominate Crypto, But Other Projects Suffer, Analyst Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$CAKE

$DOGE

$ETH

$JTO

$SHIB

$SOL

$XCN

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Climb Higher As Inflation Volatility Eases: 'Don't See A Reason To Go Back To Lows,' Trader Says

AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) stock is trading higher on Wednesday after Goldman Sachs disclosed a stake <a href="https://www.benzinga.com//node/43665086">in the company</a>.
The Details: Through a 13G filing with the Securities and Exchange Commission (SEC), Goldman revealed a 6.5% stake in AMC as of December 31. The stake is equal to roughly 24,420,283 shares.
Back in early December, AMC <a href="http://Back in early December, AMC entered into a sales agreement with Goldman Sachs, allowing it to sell up to 50 million Class A shares directly to the firm. AMC said it planned to use the proceeds from the agreement to strengthen its balance sheet and reinvest in its core business.">entered</a> into a sales agreement with Goldman, allowing it to sell up to 50 million Class A shares directly to the firm. The company said it planned to use the proceeds from the agreement to strengthen its balance sheet and reinvest in its core business.
What Else: AMC is expected to release its earnings for the 2024 fiscal-year fourth-quarter on February 25. Analysts estimate a loss of 18 cents per share and revenue of $1.33 billion.
Ahead of earnings, Roth MKM analyst Eric Handler upgraded AMC from a Sell rating to a Neutral rating and lowered the price target from&nbsp;$4&nbsp;to&nbsp;$3.25.
How To Buy AMC Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in AMC's case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/insights/analyst-ratings/25/02/43670516/the-analyst-verdict-kilroy-realty-in-the-eyes-of-7-experts">The Analyst Verdict: Kilroy Realty In The Eyes Of 7 Experts</a>
AMC Price Action: At the time of writing, AMC shares are trading 6.04% higher at $3.50, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

What's Going On With AMC Shares Wednesday?

<a href="https://x.com/Capitol_Forum/status/1889756301325996124" title="https://x.com/Capitol_Forum/status/1889756301325996124">https://x.com/Capitol_Forum/status/1889756301325996124</a>

OSCR

CORRECTION: Watching Oscar Health; The Capitol Forum Posts On X "Oscar Health Accused Of Misusing No Surprises Act To Delay Payments, Underpaying CA Health Systems"

Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $27.0, along with a high estimate of $31.00 and a low estimate of $24.00. Witnessing a positive shift, the current average has risen by 3.85% from the previous average price target of $26.00.
<img src="https://www.benzinga.com/files/images/story/2025/1739390462_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Curbline Properties among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Goldfarb</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Curbline Properties. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Curbline Properties compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Curbline Properties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Curbline Properties's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CURB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Curbline Properties analyst ratings.</a>
<h2>About Curbline Properties</h2>
Curbline Properties Corp is a publicly-traded REIT operating Convenience retail properties, offering enhanced access and visibility relative to other retail property types. The properties generally consist of a ubiquitous row of shop units along with dedicated parking leased to a diversified mixture of national and local service and restaurant tenants that cater to daily convenience trips from the growing suburban population.
<h3>Key Indicators: Curbline Properties's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Curbline Properties showcased positive performance, achieving a revenue growth rate of 22.92% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Curbline Properties's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -52.1%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Curbline Properties's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.14%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Curbline Properties's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.1%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CURB

Analyst Expectations For Curbline Properties's Future

In the latest quarter, 4 analysts provided ratings for Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 32.85% lower than the prior average price target of $34.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739390453_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Staar Surgical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Staar Surgical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>A Deep Dive into Staar Surgical's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.31%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Staar Surgical's ROE excels beyond industry benchmarks, reaching 2.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STAA

Analyst Expectations For Staar Surgical's Future

Ratings for OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.88, a high estimate of $40.00, and a low estimate of $26.00. A decline of 2.21% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1739390446_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive OneStream. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Chris Quintero</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OneStream. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OneStream compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of OneStream's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of OneStream's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OneStream analyst ratings.</a>
<h2>Discovering OneStream: A Closer Look</h2>
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.
<h3>Key Indicators: OneStream's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: OneStream displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.69%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -133.14%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -80.43%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): OneStream's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -30.44%, the company may face hurdles in achieving optimal financial returns.
Debt Management: OneStream's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss OneStream Stock

21 analysts have shared their evaluations of Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $38.71, a high estimate of $45.00, and a low estimate of $29.00. Surpassing the previous average price target of $35.67, the current average has increased by 8.52%.
<img src="https://www.benzinga.com/files/images/story/2025/1739390435_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Exelixis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$33.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Exelixis's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Unveiling the Story Behind Exelixis</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 14.33%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.37%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 4.12%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Fidelity National Info and provided 12-month price targets. The average target is $94.0, accompanied by a high estimate of $126.00 and a low estimate of $80.00. Experiencing a 6.0% decline, the current average is now lower than the previous average price target of $100.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739390427_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Fidelity National Info is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Buy</td>
<td>$113.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$126.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fidelity National Info. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Fidelity National Info compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Fidelity National Info's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FIS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fidelity National Info analyst ratings.</a>
<h2>About Fidelity National Info</h2>
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
<h3>Fidelity National Info's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Fidelity National Info showcased positive performance, achieving a revenue growth rate of 3.13% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.72%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Fidelity National Info's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.33%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Fidelity National Info's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.65%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.66, Fidelity National Info adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Fidelity National Info Through 12 Analysts

AMETEK's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) short percent of float has fallen 7.69% since its last report. The company recently reported that it has 1.97 million shares sold short, which is 0.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.28 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AMETEK Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739390424_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AMETEK has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AMETEK's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AMETEK's peer group average for short interest as a percentage of float is 10.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into AMETEK's Recent Short Interest

Eyenovia (EYEN) announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchas...

Eyenovia announces pricing of $1.9M registered direct offering

The latest update is out from Eyenovia ( ($EYEN) ). Eyenovia, Inc. has announced a $1.9 million registered direct offering, selling common stock an...

Eyenovia's $1.9M Offering to Boost Optejet Development

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Eyenovia (EYEN) announced that the two leading independent proxy advisory firms, Institutional Shareholder Services and Glass Lewis & Co., have rec...

Eyenovia announces advisory firms recommend vote 'FOR' reverse stock split

Eyenovia (EYEN) announced that its board of directors approved a 1-for-80 reverse stock split of its outstanding shares of common stock, $0.0001 pa...

Eyenovia announces 1-for-80 reverse stock split

Eyenovia approves 1-for-80 reverse stock split; shares slip

19:50 EST Eyenovia (EYEN) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

Eyenovia trading halted, news pending

These are the upcoming stock splits for the week of February 3 to February 7, based on&nbsp;TipRanks' Stock Splits Calendar. A&nbsp;stock split&nbs...

Upcoming Stock Splits This Week (February 3 to February 7) – Stay Invested

Eyenovia (EYEN) announces recent progress on the development of its user-filled spray dispenser. "Millions of consumers have difficulty with tradit...

Eyenovia announces progress on next-gen user-filled Optejet

ACSAY

ANAB

AUPH

BGNE

CDTX

CLRB

CMRX

GCTK

JAGX

MIST

MRNS

PGEN

QURE

RCKT

SGMO

VSTM

XFOR

Press Releases

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Eyenovia Provides Update on Phase 3 CHAPERONE Study

Eyenovia Provides Update on Restructuring Efforts

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

Financing

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote "FOR" Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Eyenovia Announces 1-for-80 Reverse Stock Split

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Akanda

Artelo Biosciences

Avenue Therapeutics

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Hoth Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

cbdMD

HC Wainwright & Co.

<h2 class="wp-block-heading">블록에 신규 등장</h2>
TD 은행, 또는 토론토 도미니언 은행(TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>)이 찰스 슈왑에 대한 10.1% 지분 매각을 고려 중이다. 이 매각은 이 캐나다 은행의 <a href="https://www.benzinga.com/government/24/10/41271816/td-bank-to-face-3b-penalty-growth-limits-in-us-settlement-over-anti-money-laundering-failures">미국 자금 세탁 스캔들</a>에 따른 전략적 검토의 일환이다.
TD 은행의 신임 CEO인 레이먼드 천(Raymond Chun)이 <a href="https://www.bloomberg.com/news/articles/2025-01-07/td-mulling-fate-of-schwab-stake-in-review-incoming-ceo-says?srnd=phx-deals">블룸버그</a>에 이 과정을 확인했다.
한편, 아이노비아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>)는 뉴욕에 본사를 둔 투자은행 차단(Chardan)을 고용하여 역합병(reverse merger) 또는 매각을 모색하고 있다. 안과 기술 회사인 아이노비아는 현금을 아끼면서 <a href="https://www.benzinga.com/general/biotech/24/08/40514648/why-is-eye-disease-focused-eyenovia-stock-trading-higher-on-thursday">Gen-2 Optejet 기기기</a> 개발을 계속 진행하고 싶어한다.
아이노비아는 지출을 60% 줄임으로써 재정적 자원을 늘려 더 많은 시간을 확보하고 있다. 잠재적 기회가 거래로 이어질지는 두고 봐야 할 일이다.
스마트 쉐어 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>)도 인수 제안을 검토 중이다. 현재까지는 트러스타 캐피털(Trustar Capital) 만이 주당 62센트에 회사를 비공개로 전환하겠다는 제안을 했다. 이는 <a href="https://www.benzinga.com/news/small-cap/25/01/42809956/why-is-smart-share-global-stock-surging-premarket-on-monday">매력적인 74.8% 프리미엄</a>이다.
스마트 쉐어는 2024년 중반 기준으로 4억 4천 9백만 달러의 재무적 전쟁 자금을 보유하고 있었다.
마지막으로, 워버그 핀커스(Warburg Pincus)는 플로리다 보카러톤에 본사를 둔 의료 소프트웨어 회사인 모더나이징 메디신(Modernizing Medicine)의 매각을 검토 중이다. 로이터에 따르면, 경매는 50억 달러 이상의 입찰을 유치할 수 있다.
<h2 class="wp-block-heading">블록에서 제외</h2>
레벨리스트(Revelyst), 전 비스타 아웃도어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>)의 유닛으로 자전거 관련 브랜드를 포함한 이 회사가 11억 2,500만 달러 규모의 거래의 일환으로 투자 회사 스트래티직 밸류 파트너스(Strategic Value Partners)에 의해 공식적으로 인수되었다.
트루 릴리전(True Religion), 유명한 두꺼운 스티칭으로 견고함을 자랑하는 청바지 브랜드가 새로운 주인을 맞이했다. <a href="https://www.latimes.com/business/story/2020-04-13/true-religion-files-for-bankruptcy-again-as-denims-allure-fades">두 번의 파산</a>를 겪은 후, 이 브랜드는 의류 회사와 사모펀드로부터 제안을 받기 시작했다. CNBC가 작년에 <a href="https://www.cnbc.com/2024/02/15/jeans-brand-true-religion-exploring-sale.html">보도</a>한 바와 같이, 에이콘 인베스트먼츠(Acon Investments)가 아메리칸 이글의 CEO 제이 쇼텐스타인이 이끄는 펀드와 협력하여 최종 입찰자로 선정되었다.
참고: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42913622/dollar-soars-to-27-month-highs-30-year-yields-hit-5-stocks-tumble-jobs-report-oil-spike-darken-feds-interest-rate-cut-hopes">달러가 27개월 만에 최고치로 상승하고 30년 만기 수익률이 5%에 도달하며 주식이 하락한 이유</a>
<h2 class="wp-block-heading">블록 업데이트</h2>
휴스턴에 본사를 둔 가스 발전 회사인 칼파인(Calpine)은 콘스텔레이션 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)로부터 300억 달러의 인수 제안을 받았다. 콘스텔레이션 에너지는 &#8220;배출가스 없는&#8221; 메시지로 알려진 원자력 발전 대기업이다. 이 거래는 엑셀론(Exelon)에서 분리된 후 주가가 두 배로 상승한 콘스텔레이션의 중요한 전환점을 나타낸다. 칼파인은 2018년에 에너지 캐피털 파트너스, 엑세스 인더스트리 및 CPP 인베스트먼츠에 의해 170억 달러에 인수된 바 있다. 칼파인을 인수하면 콘스텔레이션의 주요 가스 발전 포트폴리오가 포함되어 <a href="https://www.benzinga.com/topic/green-energy">친환경 에너지 브랜딩</a>에 대한 재고가 필요하게 된다.
월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)와 푸보tv(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)는 <a href="https://www.benzinga.com/general/entertainment/25/01/42857294/fubo-gets-fairy-tale-outcome-analyst-says-disney-deal-lowers-risks-overhang-on-stock">라이브 TV 스트리밍 사업</a>을 합병하기로 합의했다. 디즈니는 푸보에 70%의 지분을 확보하고, 결합된 법인은 620만 명의 가입자를 보유한 북미에서 두 번째로 큰 라이브 TV 스트리머가 된다. 유튜브 TV에 이어지는 수치이다. 훌루 + 라이브 TV는 이 거래에 포함되며, 나머지 훌루는 독립적으로 남게 된다. 이 협정의 일환으로, 푸보는 <a href="https://www.benzinga.com/markets/equities/24/09/40855153/fubotvs-lawsuit-against-disney-fox-and-warner-scheduled-for-october-2025-trial-report">디즈니 지원 베뉴 스포츠(Venu Sports)</a>에 대한 소송을 철회한다. 디즈니와 그 파트너들은 푸보에 2억 2천만 달러를 지급하고, 디즈니는 2026년 만기 1억 4천 5백만 달러의 만기 대출을 제공한다. 이 거래가 규제 문제로 인해 성사되지 않을 경우 1억 3천만 달러의 해지 수수료도 포함되어 있다.
KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)는 후지 소프트(FUJI SOFT) 주주들을 위한 제안 기간을 1월 9일부터 1월 24일까지 연장하고, 베인 캐피털의 공격적인 인수 시도를 초월하기를 바라는 듯 보인다. 한편, 베인 캐피털은 &#8220;적대적 부분 인수&#8221; 모드로 전환했다. 그러나 KKR은 최대 주주로서 베인 캐피털의 제안이 <a href="https://www.benzinga.com/25/01/42894417/kkr-extends-tender-offer-for-fuji-soft-amid-bain-capitals-hostile-bid">실행력을 얻지 못할 것</a>이라고 확신하고 있다고 알려졌다.
페이첵스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)는 페이코 HCM(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>)을 41억 달러에 현금 거래로 인수하여 주당 22.50달러를 제시했다. 이는 페이코의 최근 거래 평균에 비해 19% 프리미엄이다. 양사 이사회에서 만장일치로 승인된 이번 인수는 <a href="https://www.benzinga.com/25/01/42855388/paychex-buys-paycor-41-billion-deal-to-strengthen-ai-driven-hr-solutions">규제 승인</a>을 기다리는 동안 2025년 상반기에 완료될 예정이다.
굿이어 타이어 앤드 러버 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>)는 스미토모 러버 인더스트리(SRI)에 <a href="https://www.benzinga.com/25/01/42873285/goodyear-sells-dunlop-brand-to-sumitomo-rubber-expects-65-million-annual-soi-impact">던롭 브랜드를 매각</a>하는 거래를 체결했다. 이 거래는 현금 <a href="https://www.benzinga.com/pressreleases/25/01/n42865505/goodyear-announces-sale-of-dunlop-brand-to-sumitomo-rubber-industries" target="_blank" rel="noreferrer noopener">약 7억 1천만 달러의 매각 대금</a>을 포함한다. 이 금액은 유럽, 북미 및 오세아니아 전역의 브랜드 이전 비용, 전환 지원 수수료 및 던롭 타이어 재고 구매 비용을 포함한다. 이 거래에는 지속적인 오프테이크, 라이센스 및 기타 상업적 계약도 포함된다. 던롭 브랜드에는 유럽, 북미 및 오세아니아 전역의 소비자, 상업 및 전문 타이어에 대한 상표 및 관련 무형 자산이 포함된다. 이 거래에 따라 Goodyear는 최소한 2025년 12월 31일까지 유럽에서 던롭 소비자 타이어의 생산 및 유통을 계속하며, SRI에 로열티를 지급하고 모든 수익을 유지한다.
이탈리아의 방카 Ifis가 수요일에 2억 9,800만 유로(3억 0,900만 달러)의 주식과 현금으로 일리미티 은행 S.p.A.를 인수하겠다고 제안했다.
<h2 class="wp-block-heading">파산 블록</h2>
프로스펙트 메디컬 홀딩스(Prospect Medical Holdings)는 법률 회사 시들리 오스틴(Sidley Austin) 및 컨설팅 회사 알바레즈 앤 마살(Alvarez &amp; Marsal)과 협력하여 재정적 어려움에 처한 코네티컷 주 병원 3곳의 구조조정을 진행 중이다. <a href="https://www.wsj.com/articles/prospect-medical-explores-restructuring-56ab7a48" target="_blank" rel="noreferrer noopener">월스트리트 저널</a>에 따르면, 프로스펙트는 2016년에 병원(워터버리, 맨체스터 및 버넌)을 인수했다. 예일 뉴헤이븐 헬스 시스템(Yale New Haven Health System)은 2022년에 병원들을 4억 3,500만 달러에 인수할 의향이 있었으나, 합의는 이루어지지 않았다. 금요일 현재 병원들은 아직 파산 신청을 하지 않았다.
Corsa Coal(TSXV:<a class="ticker" href="https://www.benzinga.com/stock/CSO#TSXV">CSO</a>)은 1월 6일 미국 펜실베이니아 서부 지방법원에 자발적으로 챕터 11 파산 구제를 신청했다. 자산 매각을 진행할 예정이다. 이 회사는 파산 및 매각 과정에서 운영을 지원하기 위해 1,500만 달러의 채무자 인수 자금 지원을 약속했다.
<h2 class="wp-block-heading">블록의 메모</h2>
<ul>
<li><a href="https://www.ft.com/content/ac3c1e2f-c9bc-417e-a686-7170e1bf8533">파이낸셜 타임스</a>에 따르면, 2024년 동안 최소 686개의 미국 회사가 파산을 신청했다. </li>
<li>이는 2023년 대비 약 8% 증가한 수치이다. 또한 2010년의 828건 이후 가장 높은 수치이다. 당시 기업들은 금융 위기로 인해 여전히 어려움을 겪고 있었다.</li>
<li>작년의 파산 신청 기업 중 최소 30개는 파산 시점에 부채가 10억 달러 이상이었다. 이는 S&amp;P 글로벌 시장 정보의 데이터를 인용한 것이다.</li>
<li>2024년의 주요 파산 사례로는 파티 시티, 타파웨어, 레드 랍스터, 스피릿 항공 및 아본 프로덕츠 등이 있다.</li>
<li>부채 관리 작업이 점점 더 일반화되고 있다는 점은 주목할 만하다. 이러한 법정 밖 회의는 파산에 대한 우회책이나 대안으로 활용된다.</li>
<li>조슈아 클락(Joshua Clark), 피치 레이팅스(Fitch Ratings)의 선임 이사는 이러한 절차를 거치는 많은 기업들이 부채 계약이 무산되면 결국 파산에 이를 것이라고 언급했다.</li>
</ul>
지난주의 ‘딜 디스패치'에 대한 자세한 내용은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EB%B2%A0%EB%9D%BC-%EB%B8%8C%EB%9E%98%EB%93%A4%EB%A6%AC%EB%8A%94-%EB%AA%85%EC%95%94%EC%9D%B4-%ED%98%BC%EC%9E%AC%EB%90%9C-%ED%95%B8%EB%93%9C%EB%B0%B1/" target="_blank" rel="noopener">여기를 클릭하세요</a>.
 
지금 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/42877452/27-million-price-tag-for-late-hasbro-ceos-beverly-hills-oasis">故 해즈브로 CEO의 비벌리힐스 오아시스 가격 2,700만 달러</a></li>
</ul>


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Eyenovia

뉴스

에 대한 최신 뉴스 Eyenovia (NASDAQ:EYEN) 주식

토요일, 1월 11, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌